1. Bedard, P. L., Hyman, D. M., Davids, M. S. & Siu, L. L. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet 395, 1078–1088 (2020).
2. Flaherty, K. T., Le, D. T. & Lemery, S. Tissue-agnostic drug development. Am. Soc. Clin. Oncol. Educ. Book 37, 222–230 (2017).
3. FDA. FDA Approves Entrectinib for NTRK Solid Tumors and ROS-1 NSCLC https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc (2019).
4. FDA. FDA Approves Larotrectinib for Solid Tumors with NTRK Gene Fusions https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions (2018).
5. FDA. FDA Approves Pembrolizumab for Adults and Children with TMB-H Solid Tumors https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors (2020).